A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Highly Selective NaV1.8 Inhibitor JKN2306 in Healthy Chinese Subjects
Abstract
JKN2306 is a novel, highly selective Nav1.8 inhibitor under development for the treatment of acute pain. This first-in-human study aimed to evaluate its safety, tolerability, pharmacokinetics, and food effect (FE). This was a single center, randomized, double-blind, placebo controlled, single ascending dose (SAD) and FEstudy in healthy Chinese subjects. In the SAD part, 44 subjects were randomized to receive a single oral dose of JKN2306 (10, 30, 100, 200, or 400 mg) or placebo. The FE part was a sequential, two-period crossover study in 14 subjects from the 200 mg SAD cohort, who received a single 200 mg dose under fasting and fed conditions. Forty-four subjects were enrolled and completed the study. JKN2306 was safe and well-tolerated across all doses. Treatment-emergent adverse events were mostly Grade 1, with no serious adverse events or dose limiting toxicities. No clinically significant effects on QTc interval were observed. JKN2306 was rapidly absorbed, with Tmax of 1.50-2.50 h. The t1/2 ranged from 13.93 to 29.82 h. Exposure (Cmax and AUC) increased approximately linearly with dose over the 10-400 mg range. Food intake delayed the median Tmax by 1 h and reduced Cmax by about 17%, but had no significant effect on AUC. JKN2306 exhibits a favorable safety and tolerability profile and predictable linear PK in healthy subjects. Food has a modest effect on the rate but not the extent of absorption. These findings support the further clinical development of JKN2306 for the…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 44 participants or records.
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.